Foxfarma B.V. Sustainability Profile
Foxfarma B.V., a prominent player in the pharmaceutical industry, is headquartered in the Netherlands and operates across various regions in Europe. Founded in 2010, the company has established itself as a leader in the development and distribution of innovative healthcare solutions, focusing on both prescription and over-the-counter products. Specialising in high-quality pharmaceuticals, Foxfarma B.V. is recognised for its commitment to research and development, ensuring that its offerings meet the evolving needs of healthcare professionals and patients alike. The company’s unique approach combines cutting-edge technology with rigorous quality control, setting it apart in a competitive market. With a strong market position, Foxfarma B.V. has achieved notable milestones, including strategic partnerships and a growing portfolio of successful products. This dedication to excellence continues to drive the company’s mission of improving health outcomes across its operational regions.
DitchCarbon Score
How does Foxfarma B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Foxfarma B.V.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Foxfarma B.V.'s reported carbon emissions
Foxfarma B.V., headquartered in the Netherlands (NL), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Foxfarma B.V. may inherit climate commitments and data from its parent organisation; however, no specific details regarding such cascaded data or initiatives have been provided. This lack of information suggests that Foxfarma B.V. is still in the early stages of establishing its carbon emissions reporting and climate action strategies. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate commitments and transparent emissions reporting. As Foxfarma B.V. develops its sustainability framework, it may consider aligning with industry standards and best practices to enhance its environmental performance and accountability.
How Carbon Intensive is Foxfarma B.V.'s Industry?
How Carbon Intensive is Foxfarma B.V.'s Location?
Foxfarma B.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Foxfarma B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
